Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atorvastatin 40 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

NCT02097589
View directory record Official record
Conditions
Healthy Controls
Interventions
Atorvastatin, Pneumovax 23, Placebo (lactose pill)
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

NCT01175148
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Atorvastatin calcium (Lipitor)
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

NCT02437084
View directory record Official record
Conditions
Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
Interventions
Atorvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 21, 2026, 10:16 PM EDT
Active, not recruiting Phase 4 Interventional

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

NCT03417388
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Atorvastatin

NCT00960323
View directory record Official record
Conditions
Healthy
Interventions
Colchicine, Atorvastatin
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

NCT00296374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
29
States / cities
Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Imaging of Coronary Plaques in Participants Treated With Evolocumab

NCT03570697
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Evolocumab, Placebo, Statin therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

NCT02603328
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee

NCT01645176
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Hydroxychloroquine/Atorvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 21, 2026, 10:16 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of Lipitor on Aortic Stenosis

NCT00590135
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
atorvastatin (Lipitor)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AED/Statin Interaction Study

NCT00627575
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine, atorvastatin, phenytoin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

NCT01988571
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 100 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

NCT01491958
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
atorvastatin, Tacrolimus, methotrexate
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Healthy Participants

NCT03929744
View directory record Official record
Conditions
Healthy
Interventions
LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

NCT00616772
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Placebo, Atorvastatin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
45 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
124
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

NCT01279590
View directory record Official record
Conditions
Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions
PPD10558, Atorvastatin, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
67
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2011 · Synced Sep 21, 2026, 10:16 PM EDT
Recruiting Phase 2 Interventional

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183
View directory record Official record
Conditions
Hearing Loss, Head and Neck Cancer
Interventions
Placebo, Atorvastatin
Other · Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

NCT03611010
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemias
Interventions
Atorvastatin injection
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

NCT00465088
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Niacin ER/Simvastatin Tablets, atorvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Anaheim, California • Huntington Park, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2011 · Synced Sep 21, 2026, 10:16 PM EDT
Active, not recruiting Phase 2 Interventional

Statins for the Treatment of NASH

NCT04679376
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 21, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

NCT02370784
View directory record Official record
Conditions
Scleroderma
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 21, 2026, 10:16 PM EDT